Specialized Drug Delivery Kashiv BioSciences focuses on advanced drug delivery platforms such as delayed release and gastric retention systems, which present opportunities to collaborate with healthcare providers seeking innovative formulations to enhance drug efficacy and patient safety.

Robust Pipeline With a growing pipeline including 505(b)(2) products, biosimilars, and complex generics, Kashiv offers potential avenues for partnerships in product co-development, licensing, and expanding their portfolio in unmet therapeutic areas.

Global Expansion Headquartered in the US with operations in India, Kashiv’s international footprint suggests opportunities to target emerging markets with innovative biosimilar and generic medicines, especially in oncology and immunology fields.

Strategic Acquisitions Following its acquisition of assets from Adello Biologics, Kashiv demonstrates a capacity for strategic growth through assets in biosimilars, opening possibilities for sales collaborations in high-demand therapeutic segments.

Financial Capacity With significant funding of 150 million dollars and revenues between 100 and 250 million dollars, Kashiv has the financial leverage to explore new development partnerships, joint ventures, and licensing deals to expand their product offerings.